Product Reports Resources Pricing Login Book a demo

OM1

Biotech & Life Sciences · Boston, United States · Founded 2015

OM1 is a healthcare technology and data analytics company that focuses on improving patient outcomes through advanced data insights and artificial intelligence (AI). The company operates in the healthcare market, specifically targeting chronic diseases and conditions such as chronic rhinosinusitis and nonalcoholic steatohepatitis (NASH). OM1 serves a diverse range of clients including pharmaceutical companies, healthcare providers, and integrated delivery networks (IDNs). OM1's business model revolves around the collection, analysis, and application of real-world data (RWD). Real-world data refers to health information collected from various sources outside of traditional clinical trials, such as electronic health records (EHRs), insurance claims, and patient registries. By leveraging this data, OM1 generates real-world evidence (RWE) which helps in understanding how treatments perform in everyday clinical settings. The company makes money by offering its data analytics services and AI-driven platforms to its clients. One of its key products is Aspen, an automated evidence generation platform that helps in predicting patient outcomes and generating insights for better healthcare decisions. OM1 also partners with major healthcare organizations, such as Medtronic, to conduct studies and assess long-term patient outcomes. OM1's innovative approach includes using AI to identify patients with specific conditions, such as generalized pustular psoriasis (GPP), and to predict treatment outcomes. This helps healthcare providers deliver more precise and effective care. The company is also actively involved in thought leadership and industry discussions, as evidenced by its participation in events like the ISPOR 2024 meeting. In summary, OM1 is revolutionizing healthcare by providing actionable insights through advanced data analytics and AI, ultimately aiming to improve patient outcomes and support the development of new treatments. Keywords: healthcare technology, data analytics, AI, real-world data, patient outcomes, chronic diseases, pharmaceutical companies, healthcare providers, evidence generation, predictive medicine.

Valuation $100–500M
Revenue $10–50M
Headcount <100
Total funding $100–500M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for OM1 and the history behind them.

Investors

9 investors on OM1's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
General Catalyst
7wire Ventures
Wanxiang Healthcare Investments
Polaris Partners
Series B+ 5 investors entered at this stage
Scale Venture Partners
Breyer Capital
Kaiser Permanente
D1 Capital Partners
Glikvest

Global footprint

Where OM1 has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States65.6%
🇮🇳 India30.2%
🇧🇷 Brazil1%
🇩🇪 Germany1%
🇫🇷 France1%
Top 5 of 6 shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States98.2%
🇬🇧 United Kingdom2.7%
Top 2 markets shown

Talent graph

The shape of OM1's talent

Dealroom maps OM1's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org
13 AI specialistsincl. 3 core researchers
99 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock OM1's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about OM1

An AI-synthesized read of the highest-engagement posts about OM1 on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OM1 on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.